Determining the appropriate amount of carboplatin for a patient requires careful consideration of renal function, as measured by creatinine clearance. This calculation ensures that the drug’s concentration in the body remains within a safe and effective therapeutic range, minimizing toxicity while maximizing its anti-cancer effects. The most widely used method for this calculation involves the Calvert formula, which takes into account the target Area Under the Curve (AUC) along with creatinine clearance and, ideally, the patient’s glomerular filtration rate (GFR).
Accurate carboplatin dosage is crucial for optimal treatment outcomes and the prevention of adverse reactions. Overdosing can lead to severe myelosuppression (bone marrow suppression), resulting in anemia, neutropenia, and thrombocytopenia, which increase the risk of infection and bleeding. Conversely, underdosing can compromise the effectiveness of the chemotherapy regimen, potentially leading to disease progression. Historically, fixed-dose carboplatin regimens were common, but the recognition of significant interpatient variability in drug clearance led to the development and adoption of individualized dosing strategies based on renal function.
